SCHEMBL3202550

SCHEMBL3202550

NCCc1cn(S(=O)(=O)c2ccc3c(c2)NC(=O)CO3)c2cccnc12

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PKM P14618 5/20 0.45
NR3C2 P08235 3/20 0.43
HTR1A P08908 1/20 0.42
HTR1D P28221 1/20 0.42
HTR1B P28222 1/20 0.42
SLC6A4 P31645 1/20 0.42
KMT2A Q03164 1/20 0.42
POLB P06746 1/20 0.42
GAA P10253 1/20 0.42
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
HTR6 P50406 4/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
RAB9A P51151 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3212533 0.93 LMNA (0.42) PKMNR3C2HTR1AHTR1DHTR1B
SCHEMBL3207395 0.89 RAB9A (0.43) PKMNR3C2HTR1AHTR1DHTR1B
SCHEMBL3182560 0.82 HTR6 (0.51) PKMNR3C2KMT2AHTR6RAB9A
SCHEMBL3204495 0.82 HTR6 (0.42) PKMHTR1AHTR1DHTR1BSLC6A4
SCHEMBL3199222 0.82 LMNA (0.42) PKMNR3C2HTR1AHTR1DHTR1B
SCHEMBL3204972 0.82 HTR6 (0.43) HTR1AHTR1DHTR1BSLC6A4HTR6
SCHEMBL3182665 0.81 HTR6 (0.51) PKMNR3C2HTR6
SCHEMBL3179184 0.81 HTR6 (0.51) PKMNR3C2HTR6
SCHEMBL3210592 0.81 HTR6 (0.42) HTR1AHTR1DHTR1BSLC6A4KMT2A
SCHEMBL3208578 0.80 PPARG (0.46) PKMHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029629-A1 ACYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US claimed
US-20100029629-A1 ACYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029629-A1 ACYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
WO-2010011546-A2 ACYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-28 WO disclosed
WO-2010011546-A2 ACYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029629-A1 ACYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY HTR6, HTR1A, HTR5A PKM 2104/4885NR3C2 388/4885HTR1A 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.